Daniel L. Boeglin

Legal Counsel

Daniel L. Boeglin

Dan Boeglin is a partner with Baker & Daniels LLP. He is Chair of the firm's Business Department, which encompasses all of the business, finance, commercial and transactional practice groups. Dan has more than 20 years' experience advising companies and entrepreneurs on their strategic business initiatives, including M&A, joint venture, strategic alliance, licensing and financing transactions. For more than a decade, he has focused his practice in the life sciences industry, working extensively for clients in the pharmaceutical, medical device and biotech sectors. Dan is recognized as a leader in corporate and biotechnology law in The Best Lawyers in America and America's Leading Business Lawyers.   

Dan is a 1982 graduate of the Indiana University Kelley School of Business and a 1985 graduate of the University of Virginia School of Law. He is a former President of the Kelley School of Business Alumni Association and a former Board member of the Johnson Center for Entrepreneurship and Innovation.

www.bakerdaniels.com

Back to List

About Colucid

CoLucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company's investors include Pappas Ventures, Domain Associates, Care Capital, Pearl Street Venture Funds and Triathlon Medical Ventures.

Learn More About CoLucid

Lasmiditan

image of lasmiditan structure

Lasmiditan is a member of a novel chemical class called "ditans." Lasmiditan penetrates the central nervous system (CNS) and selectively targets 5-HT1F receptors expressed in the trigeminal nerve pathway.

Learn More About Lasmiditan